Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients. [electronic resource]
Producer: 20171023Description: 1128-1138 p. digitalISSN:- 1532-1827
- Adenocarcinoma -- drug therapy
- Adenocarcinoma of Lung
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Blotting, Western
- Carcinoma, Squamous Cell -- drug therapy
- Cell Line
- Cell Line, Tumor
- Docetaxel
- Fibroblasts -- drug effects
- Fibrosis -- pathology
- Humans
- Indoles -- administration & dosage
- Lung Neoplasms -- drug therapy
- Neoplasm Invasiveness
- Reverse Transcriptase Polymerase Chain Reaction
- Taxoids -- administration & dosage
- Transforming Growth Factor beta1 -- pharmacology
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.